Ionis Pharmaceuticals, Inc. (IONS) AI Stock Analysis

Ionis Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing RNA-targeted therapeutics. Its commercialized medicines include SPINRAZA for spinal muscular atrophy, TEGSEDI for polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis, and WAYLIVRA for familial chylomicronemia syndrome and familial partial lipodystrophy. The company's clinical pipeline includes Eplontersen, Olezarsen, Donidalorsen, ION363 for amyotrophic lateral sclerosis, Pelacarsen for cardiovascular disease, and Tofersen. Ionis maintains strategic partnerships with major pharmaceutical firms such as Biogen Inc., AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.

From FY2020 to FY2025, Ionis grew revenue at a 5-year CAGR of 5.3%. Annual revenue has fluctuated, declining 27.5% in FY2022 to $587.4M before rising 34.1% in FY2023 to $787.6M. Following a 10.5% drop in FY2024 to $705.1M, revenue increased 33.9% in FY2025 to $944.0M. Gross margins remained high, registering 98.3% in FY2025. However, elevated R&D spending, which reached $916.0M in FY2025, led to an operating margin of -40.5% and a net income of -$381.0M. In the latest quarter ending June 30, 2026, quarterly revenue fell 40.7% year-over-year, and quarterly earnings declined 43.7% year-over-year, contributing to a trailing twelve months net loss of -$3.48 per share.

As of June 30, 2026, Ionis held $2.05B in cash and short-term investments against total debt of $2.42B, resulting in net debt of $363.9M. The company maintains short-term liquidity with a current ratio of 7.88, while its debt-to-equity ratio stands at 5.50 on shareholders' equity of $439.7M. Operating cash flow in FY2025 was -$268.6M, and free cash flow was -$320.0M after capital expenditures of $51.4M. Over the trailing five years, the company's share count increased 3.4%.

Ionis carries a market capitalization of $7.14B and an enterprise value of $6.86B. The stock trades at a forward P/E of 90.9x and a price-to-sales multiple of 8.2x, both above the median of its US-listed Healthcare peers, which stand at 17.3x and 4.1x, respectively. Its enterprise value-to-EBITDA ratio is 135.8x compared to the peer median of 12.0x. Over the past year, Ionis shares dropped 41.2%, significantly lagging the S&P 500 return of 16.8%. Over five years, the stock gained 22.3% versus an 83.0% gain for the S&P 500.

Wall Street coverage includes 11 Strong Buy, 9 Buy, and 5 Hold recommendations, with no Sell or Strong Sell ratings. The average price target of $83.83 represents a 95.2% premium over the last close of $42.94. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$2.70 on revenue of $919.1M. For the following fiscal year, 10 analysts estimate revenue will reach $1.36B, reflecting 48.2% growth, alongside an improved EPS of -$1.11. Ionis has beaten EPS expectations in each of the last 4 quarters, and its next earnings release is scheduled for November 4, 2026.

This page is an AI-written research summary of Ionis Pharmaceuticals, Inc. (IONS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: IONS income statement, IONS balance sheet, IONS key metrics, IONS analyst forecast, IONS chart. See the IONS stock overview for the latest quote and news.